Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

JBIOBullishIndustry Newsnews

High materiality7/10

JADE301 preclinical data support potential best-in-class DM therapy

Sep 30, 2026, 7:40 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive preclinical strength and favorable PK/PD metrics alongside a clear Phase 1 catalyst could attract upside potential if interim safety/PK data align with expectations; however, phase-risk and lack of near-term commercialization keep upside modest absent durable data.

AI summary

What happened, with direct paths to the underlying reporting

Jade Biosciences announced strong preclinical data for JADE301, an anti-IFN-β antibody for dermatomyositis, showing potent, selective inhibition and favorable pharmacokinetics. The compound demonstrates a ~25-day subcutaneous half-life and ~73-75% human bioavailability, enabling infrequent dosing. A placebo-controlled Phase 1 in 24 healthy volunteers is planned for Q4 2026 with interim data expected in H2 2027, a key near-term catalyst for JBIO.

JADE301 shows high-affinity IFN-β neutralization; KD 11.3 pM.
SC half-life ~25 days in NHPs supports infrequent dosing.
Phase 1: 24 healthy volunteers planned Q4 2026; interim data H2 2027.
SC bioavailability ~73-75%, higher than comparator 43-44%.
GLP toxicology: well tolerated; no treatment-related adverse findings.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.